The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 22, 2015
Filed:
Dec. 09, 2005
Applicants:
John M. Centanni, Madison, WI (US);
Lynn Allen-hoffmann, Madison, WI (US);
Inventors:
John M. Centanni, Madison, WI (US);
Lynn Allen-Hoffmann, Madison, WI (US);
Assignee:
Stratatech Corporation, Madison, WI (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); A61K 35/36 (2015.01); A61K 38/18 (2006.01); A61L 27/38 (2006.01); A61L 27/60 (2006.01); C07K 14/50 (2006.01); C12N 5/071 (2010.01); A61K 38/17 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/36 (2013.01); A61K 38/1709 (2013.01); A61K 38/1825 (2013.01); A61L 27/3813 (2013.01); A61L 27/3895 (2013.01); A61L 27/60 (2013.01); C07K 14/50 (2013.01); C12N 5/0629 (2013.01); C12N 5/0698 (2013.01); A61K 35/12 (2013.01); A61K 2035/122 (2013.01); A61L 2300/252 (2013.01); A61L 2300/404 (2013.01); C12N 2501/117 (2013.01); C12N 2501/998 (2013.01); C12N 2502/094 (2013.01); C12N 2502/1323 (2013.01); C12N 2510/00 (2013.01);
Abstract
The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.